Work

Investigation of Two Dosing Schedules of Vandetanib (ZD6474), an Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, in Combination with Irinotecan in a Human Colon Cancer Xenograft Model

Year: 2007

Type: article

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-07-1094

Authors: Teresa Troiani, Natalie J. Serkova, Daniel L. Gustafson, Thomas K. Henthorn, Owen Lockerbie, Andrea Merz, Michael Long, Mark Morrow, Fortunato Ciardiello, S. Gail Eckhardt

Institutions: University of Campania "Luigi Vanvitelli", University of Colorado Denver

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Cancer Institute

Awards: Development of Mechanism-Based Anticancer Therapy, Dual Compartmental Targeting of Cancer, University of Colorado Cancer Center Support Grant

OpenAlex ID: W2151820488

FWCI: 3.027

Cites: 39

Cited by: 42

Related to: 10